pf-06687234
mAbexperimentalADC
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2016 (NCT02711462)
Timeline
Indications
Mechanism of action
- KHG/KDPG aldolaseINHIBITOR
eda inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- IL10
Oral
No
Parenteral
No
Topical
No
Also known as
- pf-06687234
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03414788 | Phase 1 | Oct 15, 2018 | Pfizer |
| NCT03269695 | Phase 2 | Dec 20, 2017 | Pfizer |
| NCT02711462 | Phase 1 | Feb 1, 2016 | Pfizer |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 3 | 3 | 2 | 2016 |
1 organizations
Page 1 / 1